Botulinum Toxin A Market Size, Share & Trends Analysis - Global - 2023-2029 - MedCore - Includes: Aesthetic Botulinum Toxin A Market, and 1 more

Botulinum Toxin A Market Size, Share & Trends Analysis - Global - 2023-2029 - MedCore - Includes: Aesthetic Botulinum Toxin A Market, and 1 more

In 2022, the global market for botulinum toxin A, also known as Botox A. was valued at almost $6.6 billion and is projected to increase at a compound annual growth rate (CAGR) of 6.5% over the forecast period, reaching almost $10.2 billion.

Our report provides a full suite of information on the global market for botulinum toxin A, including both aesthetic and therapeutic segments. We also offer detailed data on the total botulinum toxin A procedure volume on a regional and country level, so that you can gain a comprehensive understanding of the global landscape and identify key growth opportunities.

MARKET DATA INCLUDED

Unit Sales, Average Selling Prices, Market Size & Growth Trends
Procedure Numbers

COVID-19 Impact Analysis

Market Drivers & Limiters
Market Forecasts Until 2029, and Historical Data to 2019
Recent Mergers & Acquisitions
Company Profiles and Product Portfolios
Leading Competitors

GLOBAL BOTULINUM TOXIN A MARKET INSIGHTS

The global botulinum toxin A market is experiencing significant growth, largely due to the increasing popularity and acceptance of minimally invasive cosmetic procedures, particularly injectables. As patients seek out affordable treatments with minimal downtime, injectables have become increasingly popular. Additionally, preventative treatments have gained momentum, as they have proven to be an easier and less expensive method for treating wrinkles before they become more pronounced. On the other hand, deeply etched lines may require more intensive treatments.

GLOBAL BOTULINUM TOXIN A MARKET SHARE INSIGHTS

The global botulinum toxin A market was dominated by Allergan Aesthetics, Galderma, Merz Aesthetics and Johnson & Johnson. Collectively, these companies accounted for over half of the overall market value.
In 2022, Allergan Aesthetics, which is now part of AbbVie, held the leading position in the global botulinum toxin A market. Their BOTOX® solution, an injectable containing onabotulinum toxin A, is specifically formulated for the treatment of glabellar frown lines, periorbital lines (crow's feet), and forehead lines in adults. Additionally, in February 2021, AbbVie received FDA approval for the treatment of detrusor overactivity linked with certain neurological conditions in pediatric patients.

MARKET SEGMENTATION SUMMARY

Aesthetic Botulinum Toxin A Market
Therapeutic Botulinum Toxin A Market

RESEARCH SCOPE SUMMARY

Regions: North America (Canada, United States), Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela), Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, U.K.), Central & Eastern Europe (Baltic States, Bulgaria, Croatia, Czech Republic, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Turkey, Ukraine), Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates), Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam), Africa (Algeria, Egypt, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda)
Base Year: 2022
Forecast Period: 2023-2029
Historical Data: 2019-2022
Quantitative Data: Market Size, Market Share, Market Growth Rates, Units Sold, Average Selling Prices
Qualitative Data: COVID-19 Impact, Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios
Data Sources: Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data.

WHY CHOOSE IDATA?

Experts Only – iData has been around for over 17 years and is the trusted source of intelligence, and data-driven insights for key industry players. We are made up of specialists with a sole focus on medical devices, dental devices and pharmaceuticals. Our research and consulting field of endeavor never strays from the medical device industry and, because of this, we are the number one choice for leading companies in this field.

Global Coverage – iData’s unique methodology, and its expansion to over 70 countries world-wide, has made it one of the most viable sources of intelligence for global companies along with those who plan to expand their portfolio beyond the confines of their own country. Providing procedural data at the country level is another testimony to the trusted global coverage we provide.

Attention to Detail – It’s our attention to small details, scheduling of timelines, and keen project management that makes us stand out from the rest. We are creative, and our reports include metrics such as procedure numbers, ASPs, and SKU-level insights that are not found elsewhere.

Pricing – When comparing like-with-like, iData’s prices are not only extremely competitive but also the most cost-effective. We strive for success and want the same for our clients. With the level of detail incorporated into each report alongside the extensive segmentation provided, no other report compares at our price point.